AaviGen GmbH develops organ-specific Adeno-Associated Viral vectors for precision gene therapies targeting cardiovascular and cardiopulmonary diseases. The company aims to address the high mortality rates associated with heart failure by rectifying the underlying cellular and molecular dysfunctions.
Funding
$24.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Heart failure affects millions worldwide and has a high mortality rate, often surpassing many cancers. Current treatments do not fully address the underlying cellular and molecular dysfunctions that contribute to the disease. A significant portion of heart failure patients are not eligible for heart transplantation, highlighting the need for alternative therapeutic approaches.
Solution
AaviGen GmbH develops organ-specific Adeno-Associated Viral (AAV) vectors designed for precision gene therapies targeting cardiovascular and cardiopulmonary diseases. The company's proprietary next-CAP platform enables the creation of heart-specific vectors, facilitating the development of highly targeted cardiac gene therapies with enhanced safety profiles. By rectifying aberrant cellular and molecular processes, AaviGen aims to revolutionize cardiac care and improve outcomes for patients suffering from heart failure. Their approach seeks to provide a more precise and safer method for treating cardiac disease through patient-tailored biotechnological tools.
Target Audience
The primary target audience includes researchers and clinicians focused on gene therapy for cardiovascular and cardiopulmonary diseases, as well as pharmaceutical companies developing novel treatments for heart failure.
Features
- Development of novel organ-specific Adeno-Associated Viral vectors (AAV)
- Proprietary next-CAP platform for creating heart-specific vectors
- Focus on precision gene therapies targeting cardiovascular and cardiopulmonary diseases
- Designed to rectify the aberrant cellular and molecular processes which underpin heart failure
- Aims to provide a safer method for treating cardiac disease